LAROTRECTINIB IN TRK FUSION–POSITIVE SOLID TUMORS
TRK fusion–positive solid tumors represent a unique molecular subgroup of tumors that are susceptible to larotrectinib therapy. This pooled analysis of three phase I/II trials was designed to evaluate the benefit of larotrectinib in patients with TRK fusion–positive solid tumors. The objective response rate was 79%, with a complete response rate of 16%. The safety […]
LAROTRECTINIB IN TRK FUSION–POSITIVE SOLID TUMORS Read More »
